INTRODUCTION {#sec1-1}
============

*Acanthamoeba* was discovered in 1930 and since then at least 24 species have been described.\[[@ref19][@ref22]\] It is ubiquitous in nature and has been isolated from soil, fresh and brackish water, bottled mineral water, cooling towers of power plants, heating, ventilating and air conditioning units, and just about any surface that comes in contact with water, including medical and laboratory devices.\[[@ref22]\] Here we report a case of cerebral *Acanthamoeba* infection in an immunocompromised host, which was unsuccessfully treated with combination therapy including miltefosine.

CASE REPORT {#sec1-2}
===========

A 63-year-old male with a history of kidney transplantation presented to the Emergency Department for altered mental status. His wife observed the patient to have intermittent confusion for the previous 2 weeks and also noted that he was sleeping more than usual. She denied fever, nausea, vomiting, neck rigidity, photophobia, or any gross motor or sensory deficits in the patient. The patient had not traveled outside Mississippi since his transplant 6 months prior to the onset of symptoms. He was taking mycophenolate and tacrolimus for his renal allograft. On the night of admission the patient was found unresponsive in his bed. Emergency responders found the patient with marked bradycardia and a temporary pacemaker was placed en route to the hospital.

Upon arrival to the hospital the patient was arousable but unable to answer questions or follow commands. Laboratory results included the following: white blood cell count -- 9000/μL (90% neutrophils, 5% lymphocytes, 4% monocytes, 1% eosinophils), hemoglobin--10.3 g/dL, hematocrit--32.4%, platelets -- 177,000/mL, sodium -- 136 mmol/L, potassium -- 6.8 mmol/L, chloride -- 105 mmol/L, HCO~3~^-2^- 20 mmol/L, BUN -- 42 mg/dL, creatinine -- 3.4 mg/dL, lactic acid 3.7 mmol/L, troponin -- undetectable. Chest radiograph demonstrated mild cardiomegaly with clear lungs. Computerized tomography (CT) of the head showed low density areas in the left parietal, occipital and frontal lobe thought to potentially be watershed infarcts. He was admitted to the hospital with a diagnosis of ischemic stroke.

Magnetic resonance imaging (MRI) of the brain showed intracranial masses in the left frontal lobe \[[Figure 1](#F1){ref-type="fig"}\] as well as the left posterior temporal--occipital interface with edema. Dexamethasone was initiated to reduce edema and antiseizure medications were begun as well. Six days after admission, the patient underwent biopsy of the left frontal lobe lesion. This initial biopsy revealed numerous granulomata with extensive abscess formation and necrosis but no pathogens identified with special staining. Three days following the initial biopsy, another biopsy was performed in an effort to make a specific microbiological diagnosis. This second biopsy, of the left temporal region, showed multiple necrosis, gliosis, and protozoans highly suggestive of *Acanthamoeba* trophozoites \[[Figure 2](#F2){ref-type="fig"}\]. The patient was started on combination therapy with sulfadiazine, fluconazole, flucytosine, azithromycin, and miltefosine. His hospital course was complicated by declining kidney function, which ultimately required hemodialysis. The patient became pancytopenic and developed intractable fever despite broad-spectrum antibacterial therapy. He expired during his fifth week of hospitalization.

![Magnetic resonance image of the brain showing an enhancing lesion in the left frontal lobe consistent with an abscess](SNI-5-68-g001){#F1}

![Giemsa stain of brain tissue showing *Acanthamoeba* cysts (×400)](SNI-5-68-g002){#F2}

DISCUSSION {#sec1-3}
==========

Granulomatous amoebic encephalitis (GAE) is an infection of the central nervous system with a mortality rate over 50% and is increasingly recognized as an opportunistic infection of immunocompromised hosts. Reported cases of amoebic encephalitis are increasing as awareness of these pathogens and the population of immunosuppressed patients grows. GAE is caused primarily by free-living amoebae species of *Acanthamoeba*, *Sappinia*, or *Balamuthia*. Most cases are diagnosed postmortem and a limited number of cases have reported successful treatment using various combinations of antimicrobial agents.\[[@ref3][@ref7][@ref14]\] Mortality from central nervous system (CNS) amoebic infections remains extremely high and may exceed 90%.\[[@ref5]\] Currently, there is no recommended standard therapeutic regimen for CNS infections with these amoebae.

The life cycle of *Acanthamoeba* consist of two stages, a vegetative trophozoite stage and a dormant cyst stage. Under optimal conditions of nutrients, pH and temperature, trophozoitespredominate, however, under stressful conditions, a double-walled cyst is formed. The route of entry into the human body is postulated to be primarily through the lungs or breaks in the skin. The organism then disperses via blood to the brain. The most common manifestations of *Acanthamoeba* infection are related to CNS involvement. Common signs and symptoms are nonspecific and consist of headache, stiff neck, alterations in mental status or cognitive abilities, nausea, vomiting, low-grade fever, lethargy, gait or coordination disturbances, visual disturbance, focal motor deficits, seizures, or coma.\[[@ref3][@ref22]\]

Definitive diagnosis is made by examination of tissue and, rarely, by cerebrospinal fluid (CSF) analysis. CSF may show mild pleocytosis, moderately elevated protein, and low glucose, however, amoebae are frequently seen by any staining or microscopic technique. Serology for amoeba-specific antibodies is available, however, these assays are not widely available and their specificity for active disease is low since most people have been exposed to this organism at one or more times in their life. The most expeditious and common way to make the diagnosis of GAE is to demonstrate trophozoites or cysts in tissue samples.\[[@ref3]\] A unique characteristic feature of *Acanthamoeba sp*. is the presence of fine, tapering, thorn-like acanthopodia protruding from the cell. Trophozoites are 15-50 μm in size with a centrally located nucleus and a densely staining nucleolus. Cysts are 10-25 μm with two cell walls usually discernible and also demonstrate a nucleus with a dense nucleolus. The organism can also be cultivated quite readily *in vitro* in special media.\[[@ref3]\]

Currently, there is no reliably effective drug therapy for *Acanthamoeba* infection of the CNS. Most published cases have used multiple drug combinations with varying success.\[[@ref1][@ref2][@ref4][@ref6][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref15][@ref16][@ref17][@ref18][@ref20][@ref23]\] A review of the English language literature for cases of CNS infection with *Acanthamoeba* diagnosed antemortem since 2000 and which described treatment protocols is summarized in [Table 1](#T1){ref-type="table"}.

###### 

Published cases of *Acanthamoeba* encephalitis since 2000

![](SNI-5-68-g003)

Of the 18 cases in the literature, 83% (15/18) were males and 61% (11/18) had identifiable underlying immunosuppressive conditions. Mortality was 44% (8/18) and the survivors were evenly divided by the concurrence of an immunosuppressive condition. The number of cases is too small to draw any reliable conclusions about efficacy and there is a large overlap of drugs used between patients who survived and those who succumbed to infection. The Infectious Diseases Society of America (IDSA) guidelines for *Acanthamoeba* CNS infection have a CIII-level recommendation for either trimethoprim-sulfamethoxazole + rifampin + ketoconazole or fluconazole + sulfadiazine + pyrimethamine.\[[@ref21]\] Recently, the Centers for Disease Control and Prevention (CDC) announced the availability of miltefosine as an investigational drug to treat amoebic CNS infection.\[[@ref5]\] Two cases included in [Table 1](#T1){ref-type="table"} used miltefosine as part of combination therapy and both patients survived. Although the patient presented in this report was also treated with miltefosine, this drug should be strongly considered as part of combination therapy for amoebic infections of the CNS.

CONCLUSION {#sec1-4}
==========

Because of the rarity of amoebic encephalitis, it is unlikely there will be randomized clinical trials to rigorously test treatment options. Case reports and small series will remain important for identifying trends in epidemiology, natural history, and treatment of amoeba infections of the CNS. As human population demographics shift, and the number of immunosuppressed patients rises, this information will be critical to provide clinicians and laboratory workers with the most effective diagnostic and therapeutic options.

Available FREE in open access from: <http://www.surgicalneurologyint.com/text.asp?2014/5/1/68/132239>
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*Acanthamoeba* Granulomatous Amebic Encephalitis: A Challenging and Often Fatal Diagnosis

In the article "*Acanthamoeba* encephalitis: A case report and review of therapy", the authors describe a classic case of *Acanthamoeba* granulomatous amebic encephalitis (GAE) in an immunocompromised patient. Given its rarity and the specific expertise needed to make the diagnosis, *Acanthamoeba* GAE remains a challenging diagnosis. The differential diagnosis is usually that of a space-occupying brain lesion and includes more common infections like bacterial brain abscess, tuberculosis, fungal infection, neurocysticercosis, and toxoplasmosis as well as noninfectious etiologies such as malignancy or stroke. The incubation period of *Acanthamoeba* GAE is unknown although, in disseminated infections with preceding cutaneous involvement, several weeks or months may elapse between the appearance of skin lesions and the recognition of central nervous system (CNS) disease.\[[@refA6]\] Patients with *Acanthamoeba* GAE are usually immunocompromised and frequently present with an insidious and protracted onset of low-grade fever, headache, fatigue, weakness, and nausea. Patients will then progress to neurologic symptoms that may include altered mental status, hemiparesis, seizures, blurred vision, and diplopia. Other neurologic symptoms can also occur later in the course of illness such as cranial nerve palsies, dizziness, ataxia, confusion, and personality change.\[[@refA7]\] Delayed diagnosis is common because of the slowly progressive and nonspecific nature of early disease as well as a lack of awareness of this infection among clinicians. Over the course of a week to several months from the onset of neurologic symptoms, the disease almost universally progresses to coma and death from increased intracranial pressure and brain herniation.

Cerebrospinal fluid (CSF) from patients with *Acanthamoeba* GAE typically demonstrates a moderate lymphocytic pleocytosis. Protein may be elevated and glucose may be normal or low. *Acanthamoeba* organisms are rarely seen in the CSF. Computed tomography and magnetic resonance imaging scans of the brain frequently reveal single or multiple hypodense, ring-enhancing, space-occupying lesions. The diagnosis of *Acanthamoeba* GAE is usually made once affected brain tissue is obtained, whether via premortem biopsy as in the case presented here or postmortem, and amebic cysts and trophozoites are directly visualized in the tissue with hemotoxylin and eosin (H and E) staining by an experienced pathologist. The diagnosis of *Acanthamoeba* infection can be confirmed with immunohistochemical techniques that detect amebic antigen in the tissue or polymerase chain reaction (PCR) testing to detect *Acanthamoeba* DNA in the tissue.\[[@refA5]\] Confirmatory testing is only available at selected reference diagnostic laboratories including at the U.S. Centers for Disease Control and Prevention (CDC).

More often than not, *Acanthamoeba* infection is a fatal disease. Among 94 cases of *Acanthamoeba* infection reported to CDC from 1955 through 2013, mortality was 85% (CDC unpublished data). The rarity of this infection precludes the use of rigorous studies to examine effective treatment regimens; therefore, treatment recommendations rely solely on individual case reports of successful outcomes. Survivors were given multidrug regimens consisting of various combinations of pentamidine, sulfadiazine, flucytosine, fluconazole, itraconazole or voriconazole, trimethoprim-sulfamethoxazole, and miltefosine. The drug miltefosine has shown particular promise in treating free-living ameba infections, including those caused by *Acanthamoeba* and *Balamuthia mandrillaris* (a free-living ameba similar to *Acanthamoeba* that also causes GAE). Although the number of *B. mandrillaris* and *Acanthamoeba* infections treated with a miltefosine-containing regimen is small, it appears that a miltefosine-containing treatment regimen does offer a survival advantage for patients with these often fatal infections.\[[@refA1]\]

Finally, this patient\'s immunocompromised status was the result of an immunosuppressive regimen prescribed following a kidney transplant 6 months prior to symptom onset. In addition to the resulting immunosuppression, the patient\'s organ transplant also represented a possible route of exposure to *Acanthamoeba*. While there has not yet been a documented case of *Acanthamoeba* infection transmitted via solid organ transplant, the related free-living ameba, *Balamuthia mandrillaris*, has caused three clusters of organ transplant-transmitted infection when an infected donor\'s organs were transplanted into multiple recipients.\[[@refA2][@refA3][@refA4]\] In the case presented here, transplant transmission was investigated and donor testing was negative for *Acanthamoeba*. However, the potential for transplant transmission remains and clinicians should be aware of the possibility when considering the diagnosis of *Acanthamoeba* infection.

With increasing populations of immunocompromised patients, the diagnosis of *Acanthamoeba* GAE should be considered in an immunosuppressed patient with encephalitis and aggressively treated with a combination of antimicrobials. In solid organ transplant patients, the possibility of transplant-transmitted infection should be investigated so that other recipients can be prophylactically treated to prevent this deadly infection.
